Beyfortus

Aug 26, 2026

In August 2026, the U.S. FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based seasonal influenza vaccine, for adults aged 50 and older, the first flu shot in history built on the same messenger-RNA platform that powered the COVID-19 response. It is, by Moderna's own count, the company's fourth approved U.S. prod...

Jul 21, 2023

Sanofi’s immunization strategy is taking shape, owing to an authorization that could drive the company and its partner AstraZeneca to the forefront of the respiratory syncytial virus (RSV) treatment battle. The FDA approved Sanofi and AstraZeneca’s monoclonal antibody Beyfortus, also known as nirsevimab, as a preve...